Clearbridge Health Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jeremy Yee

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.5yrs
Proprietà del CEO	4.5%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jeremy Yee (54 yo)

7.5yrs

Mandato

Mr. Pinh Yee, also known as Jeremy, BA (Econ), B.Com. Pr Acct, M. Com., serves as Executive Director since 15 May 2017 and Chief Executive Officer of Clearbridge Health Ltd.Mr. Yee served as Chief Executi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Pinh Yee	CEO & Executive Director	no data	Nessun dato	4.46% SGD 83.0k
Wei Chee Tan	Financial Controller	2.1yrs	Nessun dato	Nessun dato
Kia Wei Hoo	Chief Business Officer	7.6yrs	Nessun dato	0.96% SGD 17.9k
Moi Heyang Lin	Joint Company Secretary	less than a year	Nessun dato	Nessun dato
Pei Chan Tang	Joint Company Secretary	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

Gestione esperta: Il team dirigenziale di 1H3 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Pinh Yee	CEO & Executive Director	7.5yrs	Nessun dato	4.46% SGD 83.0k
Johnson Chen	Non-Executive Non-Independent Chairman	14.8yrs	Nessun dato	17.45% SGD 324.3k
Khee Chee Soo	Member of Medical Advisory Board	6.3yrs	Nessun dato	Nessun dato
Mark Benedict Ryan	Independent Director	7yrs	Nessun dato	0.34% SGD 6.3k
How Soon Mah	Independent Director	6.7yrs	Nessun dato	Nessun dato
Andrew John Lord	Lead Independent Director	7yrs	Nessun dato	Nessun dato

7.0yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1H3 sono considerati esperti (durata media dell'incarico 7 anni).

Clearbridge Health Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Clearbridge Health Limited, Annual General Meeting, Apr 29, 2024

Clearbridge Health Limited Announces Resignation of Liau Yen San, Jonathan as Chief Operating Officer

Clearbridge Health Limited Announces Board Changes

Clearbridge Health Limited, Annual General Meeting, Jun 28, 2023

Clearbridge Health Limited Announces Retirement of Tan Soon Liang (Chen Shunliang) as Independent Director

Insufficient new directors

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: S$0.001 loss per share (vs S$0.025 loss in 3Q 2023)

New major risk - Financial position

Clearbridge Health Limited, Annual General Meeting, Apr 29, 2024

Full year 2023 earnings released: S$0.052 loss per share (vs S$0.02 loss in FY 2022)

Clearbridge Health Limited Announces Resignation of Liau Yen San, Jonathan as Chief Operating Officer

Clearbridge Health Limited to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Share price stability

New minor risk - Share price stability

New major risk - Financial position

First half 2023 earnings released: S$0.002 loss per share (vs S$0.014 loss in 1H 2022)

Clearbridge Health Limited Announces Board Changes

Clearbridge Health Limited, Annual General Meeting, Jun 28, 2023

Clearbridge Health Limited Announces Retirement of Tan Soon Liang (Chen Shunliang) as Independent Director

Full year 2022 earnings released: S$0.016 loss per share (vs S$0.032 loss in FY 2021)

Insufficient new directors

PT Lunadorii Utama Indonesia acquired SAM Laboratory Private Limited from Clearbridge Health Limited (Catalist:1H3) for SGD 8.6 million.

Clearbridge Health Limited Announces Resignation of Fexlicia Lee Pei Yue as Financial Controller

First half 2022 earnings released: S$0.013 loss per share (vs S$0.014 loss in 1H 2021)

Clearbridge Health Limited Announces Change of Company Secretaries, Effective June 24, 2022

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Clearbridge Health Limited, Annual General Meeting, Apr 26, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Clearbridge Health Limited Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Insufficient new directors

Revenue and earnings miss expectations

Full year 2020 earnings released

Clearbridge Health Limited Announces Executive Changes

Price target lowered to S$0.26

First half earnings released

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media